LVHN announces opening of new stem cell transplant center. Here’s what that means for the Lehigh Valley – The Morning Call

Lehigh Valley Health Networks Lehigh Valley Topper Cancer Institute celebrated the opening of its new Stem Cell and Transplant Therapy Program Tuesday.

Stem cell transplants are a life-saving treatment option for certain blood disorders and cancers, including numerous forms of leukemia. LVHN first announced two years ago that it would expand what was at the time an infusion suite to include stem cell transplant and cellular therapy, thanks to donations from Tom and Karin Hall. Karin Hall was treated for breast cancer at LVHN.

The program is led Dr. Amir Toor, who has more than 20 years of experience with stem cell transplants and vast expertise with cellular therapies for hematologic malignancies.

Toor said the network has spent the last few years preparing for the program by bringing together a specialized team of physicians, clinicians, nurses, social workers, financial counselors and transplant coordinators specially trained to care for and support patients undergoing stem cell transplants. He added that LVHN has also developed designated spaces where stem cells are collected for transplants and an inpatient unit designed to keep patients safe during treatment.

It is an honor to bring stem cell transplantation to people in all the communities LVHN serves, Toor said.

Stem cells are produced in bone marrow and many other tissues of the body. These cells can divide into more stem cells or turn into certain specialized cells throughout the body, such as nerve cells, cardiac muscle cells and blood cells, replacing older cells. Stem cells are essential, but some peoples bodies may not produce enough of them or they may have lost stem cells to cancer or cancer treatment.

The goal of stem cell transplants, also called bone marrow transplants, is to restore blood-forming stem cells to the body, often using a patients own preserved cells or cells from a donor, such as a family member.

Treatment through LVHNs new program will be available for people with disorders and cancers such as:

There are roughly 200 blood stem cell transplant centers that report data to the U.S. Health Resources & Services Administration, of which 11 are in Pennsylvania. Patients will often travel for this level of care, spending weeks far from home, Dr. Brian A. Nester, president and CEO of LVHN, said.

Stem cell transplants are a lifesaving treatment option, but they are also incredibly taxing for those receiving them and their loved ones, said Nester.

There are other uses of stem cells in medicine, including regenerative medicine, which uses stem cells to repair diseased, dysfunctional or injured tissue in the body. This technique can even be used to grow new organs to replace damaged ones using a patients own stem cells.

Dr. Suresh Nair, physician in chief of the Topper Cancer Institute, said that for now, LVHN will not offer regenerative medicine treatments, but this new center puts LVHN at the forefront of opportunities in future stem cell research technologies.

Visit link:
LVHN announces opening of new stem cell transplant center. Here's what that means for the Lehigh Valley - The Morning Call

Use of intravenous glutathione for skin whitening not FDA approved yet: DOH – PhilStar Life

The Department of Health (DOH) warned about the use of intravenous glutathione for skin whitening as it has not been approved yet by the Food and Drug Administration.

Health secretary Ted Herbosa reminded the public of this in a media forum on Jan. 16.

"Gusto ko sanang i-reiterate... as of now, ang FDA hindi pa po [in-a-approve] ang use ng intravenous glutathione as a skin whitening," he said.

On Jan. 9, a 39-year-old woman died in a hospital in Quezon City hours after undergoing stem cell therapy. The cause of her demise, according to her death certificate, is anaphylactic shock but the antecedent cause is glutathione and stem cell intravenous infusion, as per a Philippine STAR report.

Herbosa also added that the public should check licensed stem cell therapy clinics to avoid risks.

"Babala sa ating mga kababayan para hindi kayo mauwi sa ganitosa morguea sa inyong pagpapaganda, pagpapabata, i-check po sa [DOH] website 'yung listahan ng mga stem cell clinic na lisensyado," he said.

Glutathione is an antioxidant produced in cells made up of amino acids. According to Medical News Today it serves functions such as making DNA, supporting immune functions, regenerating vitamins C and E, and helping the liver and gallbladder. It is also believed to aid skin whitening, anti-aging, and liver and heart disease.

Although it is produced by the body naturally, glutathione can be taken orally, topically, or intravenously.

In the past, the FDA has issued warnings about using intravenous glutathione through Advisory No. 2019-182 as there are no published clinical trials evaluating its use for skin lightening.

"The FDA has not approved any injectable products for skin lightening. Injectable glutathione is approved by FDA Philippines as an adjunct treatment in cisplatin chemotherapy," the statement read.

The institution also listed some risks that come with this including toxic effects on the liver, kidneys, and nervous system.

Originally posted here:
Use of intravenous glutathione for skin whitening not FDA approved yet: DOH - PhilStar Life

Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024

MINNEAPOLIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will implement the previously announced and stockholder approved 1-for-20 reverse split of its common stock. The reverse stock split will be effective as of the morning of January 18, 2024, and the company’s common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol “PBLA.” The CUSIP number for the common stock following the reverse stock split will be 69833W404.

Read more:
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024

Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, and Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development, and Chief Medical Officer will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on January 18, 2024 at 2:30 PM ET.

Follow this link:
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference

NightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client

Project reflects Scorpius’ versatility through its multi-functional biologics facility and expertise in microbial fermentation Project reflects Scorpius’ versatility through its multi-functional biologics facility and expertise in microbial fermentation

View post:
NightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client

Pressure BioSciences’ New Consumer Products Unit Continues Long Sales Relationship with Dominant U.S. Retailer, Launching 2024 with Quarter Million…

Uncle Bud’s, PBIO’s New Consumer Products Business Unit, Kicks Off 2024 with a $252,000 Shipment of Sunburn Soother to One of the World’s Largest Retailers Uncle Bud’s, PBIO’s New Consumer Products Business Unit, Kicks Off 2024 with a $252,000 Shipment of Sunburn Soother to One of the World’s Largest Retailers

Read more from the original source:
Pressure BioSciences’ New Consumer Products Unit Continues Long Sales Relationship with Dominant U.S. Retailer, Launching 2024 with Quarter Million...

Paratek Pharmaceuticals Announces Promotion of Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer and Christopher…

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for life-threatening diseases and other public health threats, today announced two key executive team promotions. Paratek promoted Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer and Christopher Bostrom to Chief Financial Officer.

View post:
Paratek Pharmaceuticals Announces Promotion of Jonathan Light to General Counsel, Corporate Secretary and Chief Compliance Officer and Christopher...

Dewpoint Therapeutics Awarded Target ALS Grant for Development of C-mods for ALS

BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today announced that it was awarded a Target ALS Foundation grant, in collaboration with the ALS Association and The Jackson Laboratory, for an in vivo proof-of-concept study of c-mods in a chronic C9orf72 repeat, the most common genetic cause of ALS.

See the original post here:
Dewpoint Therapeutics Awarded Target ALS Grant for Development of C-mods for ALS